Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TPMT | P51580 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.31 |
| ▸ | C1S | P09871 | 1/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.31 |
| ▸ | SELL | P14151 | 1/20 | 0.30 |
| ▸ | SELP | P16109 | 1/20 | 0.30 |
| ▸ | SELE | P16581 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13312950 | 0.94 | ALDH1A1 (0.33) | ALDH1A1TSHRACHECA1CA9 | |
| SCHEMBL12400058 | 0.82 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL10243144 | 0.82 | ACHE (0.36) | ACHE | |
| SCHEMBL12262679 | 0.77 | CYP2A6 (0.38) | — | |
| SCHEMBL12399933 | 0.77 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL13172756 | 0.75 | TPMT (0.40) | HPGDL3MBTL1TPMTPRSS1PRSS2 | |
| SCHEMBL13172652 | 0.75 | TPMT (0.61) | ALDH1A1TSHRHPGDTPMTCA1 | |
| SCHEMBL13172650 | 0.73 | TPMT (0.39) | HPGDTPMT | |
| SCHEMBL1641881 | 0.73 | — | — | |
| SCHEMBL2614501 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114014838-B | Compound and preparation method and application thereof | 山东师范大学 | 2024-03-19 | — | — | CN | claimed |
| WO-2023033890-A1 | NITROGEN-CONTAINING COMPOUNDS AS ADDITIVES FOR SILICON-BASED LI-ION BATTERIES | ENEVATE CORPORATION (US) | 2023-03-09 | — | — | WO | claimed |
| CN-113956232-B | Quinoline-bisindole compound and preparation method and application thereof | 山东师范大学 | 2022-09-16 | — | — | CN | claimed |
| CN-114014838-A | Compound and preparation method and application thereof | 山东师范大学 | 2022-02-08 | — | — | CN | claimed |
| CN-113956232-A | Quinoline-bisindole compound and preparation method and application thereof | 山东师范大学 | 2022-01-21 | — | — | CN | claimed |
| EP-4079742-B1 | METAL COMPLEXES | UDC IRELAND LTD (IE) | 2026-04-01 | — | — | EP | disclosed |
| CN-114014838-B | Compound and preparation method and application thereof | 山东师范大学 | 2024-03-19 | — | — | CN | disclosed |
| WO-2023033890-A1 | NITROGEN-CONTAINING COMPOUNDS AS ADDITIVES FOR SILICON-BASED LI-ION BATTERIES | ENEVATE CORPORATION (US) | 2023-03-09 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-113956232-B | Quinoline-bisindole compound and preparation method and application thereof | 山东师范大学 | 2022-09-16 | — | — | CN | disclosed |
| CN-114014838-A | Compound and preparation method and application thereof | 山东师范大学 | 2022-02-08 | — | — | CN | disclosed |
| CN-113956232-A | Quinoline-bisindole compound and preparation method and application thereof | 山东师范大学 | 2022-01-21 | — | — | CN | disclosed |
| US-8207198-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2451814-A2 | FUSED IMIDAZOLES AND COMPOSITIONS COMPRISING THEM FOR THE TREATMENT OF PARASITIC DISEASES, SUCH AS E.G. MALARIA | IRM LLC (BM) | 2012-05-16 | — | — | EP | disclosed |
| US-20110177312-A1 | LAMINATED STRUCTURE, METHOD FOR PRODUCING SAME, AND ELECTRONIC ELEMENT COMPRISING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-07-21 | — | — | US | disclosed |
| US-20110059934-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2011-03-10 | — | — | US | disclosed |
| WO-2011006143-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2011-01-13 | — | — | WO | disclosed |
| US-20090253674-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
| US-7351389-B2 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO INTERNATIONAL B.V. (NL) | 2008-04-01 | — | — | US | disclosed |
| US-20080020981-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110177312-A1 | LAMINATED STRUCTURE, METHOD FOR PRODUCING SAME, AND ELECTRONIC ELEMENT COMPRISING SAME | EPCAM, ITGA1, ITGB1 | ALDH1A1 618/4885TSHR 4526/4885ACHE 1808/4885 |
| US-20110059934-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF PARASITIC DISEASES | SQLE, SGMS2, FDPS | ALDH1A1 1414/4885TSHR 4657/4885ACHE 208/4885 |
| US-20090253674-A1 | Substituted Triazole Derivatives As Oxytocin Antagonists | OXTR, AVPR1B, GNRHR | ALDH1A1 3751/4885TSHR 247/4885ACHE 1261/4885 |
| US-20080020981-A1 | Non-nucleoside reverse transcriptase inhibitors | SAMHD1, HPRT1, NQO2 | ALDH1A1 566/4885TSHR 3181/4885ACHE 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.